20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Allogene Therapeutics Inc (ALLO) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 150 employees. Its market capitalization is roughly $408 million. In the fiscal year ended 2025-12-31, ALLO reported $0M in revenue and ($191M) in net income.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Interactive charts & full statements → Open the ALLO valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $5M | $0M | $0M | $0M | $0M | $38M | $38M | $0M | $0M | $0M |
| Gross Profit | ($32M) | ($12M) | $0M | $0M | $0M | $38M | ($12M) | ($5M) | ($2M) | $0M |
| Gross Margin % | -699.4% | — | 100.0% | 100.0% | 100.0% | 100.0% | -30.1% | — | — | — |
| Operating Income (EBIT) | ($180M) | ($207M) | ($273M) | ($328M) | ($335M) | ($256M) | ($258M) | ($202M) | ($193M) | $0M |
| Operating Margin % | -3886.1% | — | -1241813.6% | -344986.3% | -138044.9% | -664.6% | -673.5% | — | — | — |
| Net Income | ($165M) | ($191M) | ($258M) | ($327M) | ($330M) | ($245M) | ($233M) | ($185M) | ($212M) | $0M |
| Net Margin % | -3566.7% | — | -1170863.6% | -344489.5% | -135726.3% | -636.1% | -608.9% | — | — | — |
| EBITDA | ($153M) | ($177M) | ($243M) | ($313M) | ($321M) | ($245M) | ($251M) | ($180M) | ($207M) | $0M |
| Earnings Per Share (EPS) | $-0.67 | $-0.87 | $-1.32 | $-2.09 | $-2.30 | $-1.80 | $-1.94 | $-1.83 | $-2.36 | $-0.00 |
| Shares Outstanding (M) | 329M | 221M | 195M | 157M | 143M | 136M | 120M | 101M | 90M | 44M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $5M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $5M | ($3M) | ($3M) | ($31M) | ($40M) | ($3M) | ($3M) | ($45M) |
| Gross Margin % | 100.0% | — | — | — | — | — | 14695.4% | — |
| Operating Income (EBIT) | ($47M) | ($46M) | ($42M) | ($45M) | ($57M) | ($65M) | ($60M) | ($72M) |
| Operating Margin % | -1011.2% | — | — | — | — | — | 274954.6% | — |
| Net Income | ($43M) | ($43M) | ($39M) | ($41M) | ($51M) | ($60M) | ($60M) | ($66M) |
| Net Margin % | -919.8% | — | — | — | — | — | 272450.0% | — |
| EBITDA | ($40M) | ($39M) | ($35M) | ($38M) | ($48M) | ($56M) | ($56M) | ($63M) |
| Earnings Per Share (EPS) | $-0.13 | $-0.18 | $-0.18 | $-0.19 | $-0.23 | $-0.28 | $-0.28 | $-0.32 |
| Shares Outstanding (M) | 329M | 240M | 221M | 222M | 219M | 215M | 211M | 209M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($102M) | ($149M) | ($200M) | ($238M) | ($221M) | ($185M) | ($115M) | ($137M) | ($45M) | ($45M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $2M | $5M | $21M | $66M | $51M | $3M | $5M |
| Free Cash Flow (FCF) | ($103M) | ($150M) | ($201M) | ($239M) | ($226M) | ($206M) | ($181M) | ($188M) | ($48M) | ($50M) |
| FCF Margin % | -2211.2% | — | -913609.1% | -251841.0% | -92884.8% | -535.9% | -472.2% | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($32M) | ($13M) | ($28M) | ($30M) | ($39M) | ($53M) | ($37M) | ($44M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($32M) | ($13M) | ($28M) | ($30M) | ($39M) | ($53M) | ($37M) | ($45M) |
| FCF Margin % | -692.8% | — | — | — | — | — | 167977.3% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $550M | $416M | $549M | $643M | $822M | $1.1B | $1.2B | $718M | $774M | $0M |
| Cash & Cash Equivalents | $39M | $52M | $75M | $83M | $62M | $173M | $183M | $175M | $721M | $0M |
| Total Liabilities | $114M | $123M | $127M | $131M | $155M | $126M | $148M | $89M | $71M | $0M |
| Total Debt (Short + Long-Term) | $0M | $8M | $8M | $7M | $6M | $3M | $3M | $2M | $34M | $0M |
| Total Shareholders' Equity | $436M | $293M | $422M | $512M | $667M | $925M | $1.1B | $629M | $703M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALLO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms